Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome

Zhu,Chen; Cheng,Xinwei; Gao,Ping; Gao,Qianyan; Wang,Ximin; Liu,Dong; Ren,Xiuhua; Zhang,Chengliang

doi:10.3892/mmr.2022.12862

Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome

Authors:
- Chen Zhu
- Xinwei Cheng
- Ping Gao
- Qianyan Gao
- Ximin Wang
- Dong Liu
- Xiuhua Ren
- Chengliang Zhang
View Affiliations

Affiliations: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Pharmacy, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: September 28, 2022 https://doi.org/10.3892/mmr.2022.12862
Article Number: 346
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatic sinusoidal obstruction syndrome (HSOS) is a serious side effect of oxaliplatin (OXA) treatment. The present study aimed to establish a reproducible mouse model of OXA‑induced HSOS and to preliminarily explore the underlying molecular mechanisms using mRNA microarray analysis. A total of 45 C57BL/6 male mice were randomly divided into five groups: Control, 5 mg/kg OXA, 10 mg/kg OXA, 15 mg/kg OXA and 20 mg/kg OXA. The mice were respectively injected intraperitoneally with 5% glucose solution, or 5, 10, 15 or 20 mg/kg OXA solution once a week for 6 consecutive weeks. The body weight of the mice was recorded every day. The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined. Hematoxylin and eosin staining, Sirius red staining and scanning electron microscopy were used to identify pathological changes. mRNA microarray was used to analyze changes in the gene expression profiles mainly from the functional aspects of Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. The oxidation mechanism was verified by measuring oxidative stress‑related markers and reactive oxygen species with dihydroethidium probe technology, according to the microarray results. Among all of the OXA groups, 10 mg/kg OXA resulted in an acceptable survival rate of 78%. The mice showed obvious splenomegaly, increases in serum levels of ALT and AST, aggravation of liver pathological injuries and hepatic sinusoidal injuries. The microarray results suggested that mRNA expression changes after OXA treatment were associated with ‘oxidative stress’, ‘coagulation function’, ‘steroid anabolism’ and ‘pro‑inflammatory responses’. The results confirmed that OXA aggravated oxidative damage in the livers of the mice. The present study successfully established a mouse model of OXA‑induced HSOS and preliminarily analyzed the underlying molecular mechanisms involved, thus laying a foundation for a subsequent in‑depth study.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
2	Soulié P, Raymond E, Brienza S and Cvitkovic E: Oxaliplatin: The first DACH platinum in clinical practice. Bull Cancer. 84:665–673. 1997.(In French). PubMed/NCBI
3	Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D: Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol. 27:1829–1835. 2009. View Article : Google Scholar : PubMed/NCBI
4	Duwe G, Knitter S, Pesthy S, Beierle AS, Bahra M, Schmelzle M, Schmuck RB, Lohneis P, Raschzok N, Öllinger R, et al: Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Eur J Surg Oncol. 43:1668–1681. 2017. View Article : Google Scholar : PubMed/NCBI
5	Liang XB, Hou SH, Li YP, Wang LC, Zhang X and Yang J: Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: A meta-analysis. Chin Med J (Engl). 123:3314–3318. 2010.PubMed/NCBI
6	Puente A, Fortea JI, Del Pozo C, Huelin P, Cagigal ML, Serrano M, Cabezas J, Arias LM, Iruzubieta P, Cuadrado A, et al: Porto-sinusoidal vascular disease associated to oxaliplatin: An entity to think about it. Cells. 8:15062019. View Article : Google Scholar : PubMed/NCBI
7	André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI
8	Erdem GU, Dogan M, Demirci NS and Zengin N: Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther. 12:509–514. 2016. View Article : Google Scholar : PubMed/NCBI
9	Zhao J, van Mierlo K, Gomez-Ramirez J, Kim H, Pilgrim CHC, Pessaux P, Rensen SS, van der Stok EP, Schaap FG, Soubrane O, et al: Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 104:990–1002. 2017. View Article : Google Scholar : PubMed/NCBI
10	Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 15:460–466. 2004. View Article : Google Scholar : PubMed/NCBI
11	Nassereddine S, Alsubait S and Tabbara I: Sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic stem cell transplant: Insights and therapeutic advances. Anticancer Res. 38:2597–2605. 2018.PubMed/NCBI
12	Nam SJ, Cho JY, Lee HS, Choe G, Jang JJ, Yoon YS, Han HS and Kim H: Chemotherapy-associated hepatopathy in korean colorectal cancer liver metastasis patients: Oxaliplatin-based chemotherapy and sinusoidal injury. Korean J Pathol. 46:22–29. 2012. View Article : Google Scholar : PubMed/NCBI
13	Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey JN, et al: Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 56:430–439. 2010. View Article : Google Scholar : PubMed/NCBI
14	Fan CQ and Crawford JM: Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 4:332–346. 2014. View Article : Google Scholar : PubMed/NCBI
15	Russolillo N, Langella S, Perotti S, Lo Tesoriere R, Forchino F and Ferrero A: Preoperative assessment of chemotherapeutic associated liver injury based on indocyanine green retention test. Int J Surg. 31:80–85. 2016. View Article : Google Scholar : PubMed/NCBI
16	Zhu C, Ren X, Liu D and Zhang C: Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology. 460:1528822021. View Article : Google Scholar : PubMed/NCBI
17	Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA and Kopetz S: Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 28:2549–2555. 2010. View Article : Google Scholar : PubMed/NCBI
18	Cayet S, Pasco J, Dujardin F, Besson M, Orain I, De Muret A, Miquelestorena-Standley E, Thiery J, Genet T and Le Bayon AG: Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation. Eur J Radiol. 94:180–190. 2017. View Article : Google Scholar : PubMed/NCBI
19	Han NY, Park BJ, Kim MJ, Sung DJ and Cho SB: Hepatic parenchymal heterogeneity on contrast-enhanced CT scans following oxaliplatin-based chemotherapy: Natural history and association with clinical evidence of sinusoidal obstruction syndrome. Radiology. 276:766–774. 2015. View Article : Google Scholar : PubMed/NCBI
20	Couto M and Cates C: Laboratory guidelines for animal care. Methods Mol Biol. 1920:407–430. 2019. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lu Y, Wu S, Xiang B, Li L and Lin Y: Curcumin attenuates oxaliplatin-induced liver injury and oxidative stress by activating the Nrf2 pathway. Drug Des Devel Ther. 14:73–85. 2020. View Article : Google Scholar : PubMed/NCBI
23	Li X, Zhang ZS, Zhang XH, Yang SN, Liu D, Diao CR, Wang H and Zheng FP: Cyanidin inhibits EMT induced by oxaliplatin via targeting the PDK1-PI3K/Akt signaling pathway. Food Funct. 10:592–601. 2019. View Article : Google Scholar : PubMed/NCBI
24	Miyagi A, Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D and Shimazoe T: Dimethyl fumarate attenuates oxaliplatin-induced peripheral neuropathy without affecting the anti-tumor activity of oxaliplatin in rodents. Biol Pharm Bull. 42:638–644. 2019. View Article : Google Scholar : PubMed/NCBI
25	Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, Majno PE, Mentha G and Terris B: Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther. 10:687–696. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zou X, Wang Y, Peng C, Wang B, Niu Z, Li Z and Niu J: Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin-induced model of liver injury. Int J Mol Med. 42:2020–2030. 2018.PubMed/NCBI
27	Kim MJ, Han SW, Lee DW, Cha Y, Lee KH and Kim TY, Oh DY, Kim SH, Im SA, Bang YJ and Kim TY: Splenomegaly and its associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Res Treat. 48:990–997. 2016. View Article : Google Scholar : PubMed/NCBI
28	El Chediak A, Haydar AA, Hakim A, Massih SA, Hilal L, Mukherji D, Temraz S and Shamseddine A: Increase in spleen volume as a predictor of oxaliplatin toxicity. Ther Clin Risk Manag. 14:653–657. 2018. View Article : Google Scholar : PubMed/NCBI
29	Zhang YF, Huang Y, Ni YH and Xu ZM: Systematic elucidation of the mechanism of geraniol via network pharmacology. Drug Des Devel Ther. 13:1069–1075. 2019. View Article : Google Scholar : PubMed/NCBI
30	Tsikas D: Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Anal Biochem. 524:13–30. 2017. View Article : Google Scholar : PubMed/NCBI
31	Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. 2013. View Article : Google Scholar : PubMed/NCBI
32	Vreuls CP, Van Den Broek MA, Winstanley A, Koek GH, Wisse E, Dejong CH, Olde Damink SW, Bosman FT and Driessen A: Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology. 61:314–318. 2012. View Article : Google Scholar : PubMed/NCBI
33	Tajima H, Ohta T, Miyashita T, Nakanuma S, Matoba M, Miyata T, Sakai S, Okamoto K, Makino I, Kinoshita J, et al: Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver. Mol Clin Oncol. 3:555–558. 2015. View Article : Google Scholar : PubMed/NCBI
34	Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, White SA and Mann DA: Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol. 59:318–326. 2013. View Article : Google Scholar : PubMed/NCBI
35	Lu Y, Lin Y, Huang X, Wu S, Wei J and Yang C: Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non-alcoholic fatty liver disease mouse model. Int J Mol Med. 43:2398–2408. 2019.PubMed/NCBI
36	Yang L, Ding Y, Rao S, Chen C and Zeng M: T₁ mapping on Gd-EOB-DTPA-enhanced MRI for the prediction of oxaliplatin-induced liver injury in a mouse model. J Magn Reson Imaging. 53:896–902. 2021. View Article : Google Scholar : PubMed/NCBI
37	Oneda E and Zaniboni A: Adjuvant treatment of colon cancer with microsatellite instability-the state of the art. Crit Rev Oncol Hematol. 169:1035372022. View Article : Google Scholar : PubMed/NCBI
38	Xia T, Zhang J, Han L, Jin Z, Wang J, Li X, Man S, Liu C and Gao W: Protective effect of magnolol on oxaliplatin-induced intestinal injury in mice. Phytother Res. 33:1161–1172. 2019. View Article : Google Scholar : PubMed/NCBI
39	Valla DC and Cazals-Hatem D: Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 40:378–385. 2016. View Article : Google Scholar : PubMed/NCBI
40	McCarty JH: αvβ8 integrin adhesion and signaling pathways in development, physiology and disease. J Cell Sci. 133:jcs2394342020. View Article : Google Scholar : PubMed/NCBI
41	Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al: The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell. 96:319–328. 1999. View Article : Google Scholar : PubMed/NCBI
42	Trostchansky A, Moore-Carrasco R and Fuentes E: Oxidative pathways of arachidonic acid as targets for regulation of platelet activation. Prostaglandins Other Lipid Mediat. 145:1063822019. View Article : Google Scholar : PubMed/NCBI
43	Capdevila JH, Falck JR and Harris RC: Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 41:163–181. 2000. View Article : Google Scholar : PubMed/NCBI
44	Sheets JJ, Mason JI, Wise CA and Estabrook RW: Inhibition of rat liver microsomal cytochrome P-450 steroid hydroxylase reactions by imidazole antimycotic agents. Biochem Pharmacol. 35:487–491. 1986. View Article : Google Scholar : PubMed/NCBI
45	Pikuleva IA: Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 34:513–520. 2006. View Article : Google Scholar : PubMed/NCBI
46	Jarzabek MA, Proctor WR, Vogt J, Desai R, Dicker P, Cain G, Raja R, Brodbeck J, Stevens D, van der Stok EP, et al: Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer. PLoS One. 13:e1980992018. View Article : Google Scholar : PubMed/NCBI
47	Lu SC, Mato JM, Espinosa-Diez C and Lamas S: MicroRNA-mediated regulation of glutathione and methionine metabolism and its relevance for liver disease. Free Radic Biol Med. 100:66–72. 2016. View Article : Google Scholar : PubMed/NCBI
48	Tabassum H, Waseem M, Parvez S and Qureshi MI: Oxaliplatin-induced oxidative stress provokes toxicity in isolated rat liver mitochondria. Arch Med Res. 46:597–603. 2015. View Article : Google Scholar : PubMed/NCBI